Mar 14, 2023 / 01:20PM GMT
Mark Breidenbach - Oppenheimer & Co. Inc. - Analyst
All right. Good morning, everyone. Thanks for joining us on day two of Oppenheimer's 33rd Annual Healthcare Conference. My name is Mark Breidenbach. I'm one of the biotech analysts here at Oppenheimer.
Our next presenting company is Gamida Cell, which is developing a first-in-class stem cell product for allogeneic bone marrow transplant as well as a pipeline of NK cell therapies for cancer.
So joining us this morning to walk us through the story is CEO, Abbey Jenkins; COO, CCO, Michele Korfin; and CMO, CSO, Ronit Simantov. So we'll try and leave a few minutes at the end for Q&A. So I encourage everyone or anyone in the audience who has a question to make use of the Q&A button on your screen.
And with that said, I'll hand the mic over to Abbey to walk us through the story.
Abbey Jenkins - Gamida Cell Ltd. - President & CEO
Great. Thank you, Mark, and good morning to everyone joining us today. 2023 is an exciting year for Gamida Cell. We've been working in this area,
Gamida Cell Ltd at Oppenheimer Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot